FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225530712> ?p ?o ?g. }

• W4225530712 endingPage "446" @default.
• W4225530712 startingPage "445" @default.
• W4225530712 abstract "Advanced age is a key risk factor for morbidity and mortality associated with SARS-CoV-2 infection. Therefore, older adults have generally been prioritised for COVID-19 vaccination. Moreover, lower vaccine immunogenicity and more pronounced waning of humoral immunity in older individuals than in younger individuals have prompted early booster campaigns.1Levin EG Lustig Y Cohen C et al.Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months.N Engl J Med. 2021; 385: e84Crossref PubMed Scopus (312) Google Scholar The omicron variant (B.1.1.529) of SARS-CoV-2 shows substantial resistance to vaccine-induced serum neutralising activity and hence is of particular concern.2Cele S Jackson L Khoury DS et al.Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.Nature. 2021; (published online Dec 23.)https://doi.org/10.1038/s41586-021-04387-1Crossref Scopus (178) Google Scholar Although booster immunisations can elicit omicron-neutralising activity,3Schmidt F Muecksch F Weisblum Y et al.Plasma neutralization of the SARS-CoV-2 omicron variant.N Engl J Med. 2021; 386: 599-601Crossref PubMed Scopus (78) Google Scholar their immediate and long-term effects in older individuals are not known, which limits informed guidance on vaccination strategies in this susceptible population. We longitudinally determined SARS-CoV-2-neutralising serum activity in a prospective cohort of 37 individuals with a median age of 82 years (range 76–96; appendix p 2).4Tober-Lau P Schwarz T Vanshylla K et al.Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers.Lancet Respir Med. 2021; 9: e104-e105Summary Full Text Full Text PDF PubMed Scopus (19) Google Scholar Individuals were recruited at a general practitioner surgery in Berlin, Germany, with the support of the Charité-Universitätsmedizin Berlin, and received their first COVID-19 vaccination on Jan 15, 2021. Participants were followed-up for 10 months after their second dose of BNT162b2 (Pfizer-BioNTech) and up to 4·5 months after a booster dose of BNT162b2. We determined geometric mean 50% inhibitory serum dilutions (ID50) against the Wu01 vaccine strain as well as the delta (B.1.617.2) and omicron variants (BA.1) using an in-house pseudovirus assay. After their second dose of BNT162b2, serum samples were collected at 1 month (median 26 days [IQR 25–27]; visit 1) and 5 months (median 153 days [151–154]; visit 2) of follow-up. Two BNT162b2 doses induced detectable Wu01-neutralising and delta-neutralising activity in most individuals (35 [95%] of 37 for Wu01 and 31 [84%] for delta), while activity against omicron was not or only minimally detectable (figure; appendix p 3). Over the next 4 months, Wu01-neutralising titres decreased 6-fold (from a geometric mean ID50 of 260 on visit 1 to 42 on visit 2) and delta-neutralising titres decreased 7-fold (from a geometric mean ID50 of 89 to 13). All individuals received a booster dose of BNT162b2 at 7 months (median 209 days [IQR 189–228]) and early post-boost serum samples were obtained 1 month later (median 23 days [IQR 21–29]; visit 3). Booster immunisation resulted in an over 50-fold increase in Wu01-neutralising and delta-neutralising titres (to a geometric mean serum ID50 of 2912 for Wu01 and 750 for delta). The BNT162b2 booster elicited robust omicron-neutralising activity (to a geometric mean ID50 of 256) in 33 (89%) of 37 participants (figure; appendix p 3). To determine post-boost durability of SARS-CoV-2-neutralising activity in older adults, we obtained samples 3·5 months (median 106 days [IQR 86–125]) after booster vaccination (visit 4). Neutralising titres decreased by 2·7-fold (to geometric mean ID50 of 1077) against the Wu01 variant, 2·3-fold (to 345) against the delta variant, and 3·0-fold (to 85) against the omicron variant. However, most individuals maintained detectable serum neutralisation against Wu01 (36 [97%] of 37), delta (34 [92%]), and omicron (30 [81%]; corresponding to 30 [91%] of 34 individuals with activity at the early post-boost visit [ie, visit 3]). To assess the rate of decrease in neutralising activity, we separately analysed the pre-booster (visit 1–2) and post-booster (visit 3–4) periods using linear mixed-effect models (appendix p 4). Neutralising activity against the variants showed similar changes, with estimated post-booster half-lives of 52 days (95% CI 46–59) for the Wu01 variant, 64 days (52–83) for the delta variant, and 41 days (34–52) for the omicron variant (appendix p 4). In the absence of omicron variant-specific vaccines, booster immunisations are crucial to restore vaccine effectiveness against severe outcomes.5Barda N Dagan N Cohen C et al.Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.Lancet. 2021; 398: 2093-2100Summary Full Text Full Text PDF PubMed Scopus (199) Google Scholar We found that booster immunisations can effectively elicit omicron variant-neutralising activity in the majority of older individuals. Although our analyses were limited to four sampling timepoints and different pre-boost and post-boost observational periods, our results suggest that neutralising activity against different variants decreases at similar decay rates. Although neutralising activity does not equal protection from infection, our findings suggest that previous observations on waning humoral immunity can guide subsequent booster vaccination strategies in the older population. KV, HG, and FKl are listed as inventors on patent applications regarding SARS-CoV-2-neutralising antibodies filed by the University of Cologne. All other authors declare no competing interests. KV, PT-L, and HG contributed equally. FKu, LES, and FKl contributed equally. Acknowledgments are listed in the appendix (p 7). Download .pdf (.78 MB) Help with pdf files Supplementary appendix" @default.
• W4225530712 created "2022-05-05" @default.
• W4225530712 creator A5001140229 @default.
• W4225530712 creator A5007665606 @default.
• W4225530712 creator A5040615109 @default.
• W4225530712 creator A5049675039 @default.
• W4225530712 creator A5063085323 @default.
• W4225530712 creator A5064891521 @default.
• W4225530712 creator A5067716705 @default.
• W4225530712 creator A5071560628 @default.
• W4225530712 creator A5074607200 @default.
• W4225530712 creator A5076705834 @default.
• W4225530712 creator A5086835391 @default.
• W4225530712 date "2022-04-01" @default.
• W4225530712 modified "2023-10-06" @default.
• W4225530712 title "Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults" @default.
• W4225530712 cites W3206648736 @default.
• W4225530712 cites W3210126657 @default.
• W4225530712 cites W4205412981 @default.
• W4225530712 cites W4220673385 @default.
• W4225530712 cites W4225854071 @default.
• W4225530712 doi "https://doi.org/10.1016/s1473-3099(22)00135-9" @default.
• W4225530712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35240040" @default.
• W4225530712 hasPublicationYear "2022" @default.
• W4225530712 type Work @default.
• W4225530712 citedByCount "27" @default.
• W4225530712 countsByYear W42255307122022 @default.
• W4225530712 countsByYear W42255307122023 @default.
• W4225530712 crossrefType "journal-article" @default.
• W4225530712 hasAuthorship W4225530712A5001140229 @default.
• W4225530712 hasAuthorship W4225530712A5007665606 @default.
• W4225530712 hasAuthorship W4225530712A5040615109 @default.
• W4225530712 hasAuthorship W4225530712A5049675039 @default.
• W4225530712 hasAuthorship W4225530712A5063085323 @default.
• W4225530712 hasAuthorship W4225530712A5064891521 @default.
• W4225530712 hasAuthorship W4225530712A5067716705 @default.
• W4225530712 hasAuthorship W4225530712A5071560628 @default.
• W4225530712 hasAuthorship W4225530712A5074607200 @default.
• W4225530712 hasAuthorship W4225530712A5076705834 @default.
• W4225530712 hasAuthorship W4225530712A5086835391 @default.
• W4225530712 hasBestOaLocation W42255307121 @default.
• W4225530712 hasConcept C121332964 @default.
• W4225530712 hasConcept C126322002 @default.
• W4225530712 hasConcept C1276947 @default.
• W4225530712 hasConcept C187212893 @default.
• W4225530712 hasConcept C203014093 @default.
• W4225530712 hasConcept C203165030 @default.
• W4225530712 hasConcept C22070199 @default.
• W4225530712 hasConcept C2779134260 @default.
• W4225530712 hasConcept C2780868878 @default.
• W4225530712 hasConcept C3007834351 @default.
• W4225530712 hasConcept C3008058167 @default.
• W4225530712 hasConcept C524204448 @default.
• W4225530712 hasConcept C71924100 @default.
• W4225530712 hasConcept C72563966 @default.
• W4225530712 hasConcept C8891405 @default.
• W4225530712 hasConceptScore W4225530712C121332964 @default.
• W4225530712 hasConceptScore W4225530712C126322002 @default.
• W4225530712 hasConceptScore W4225530712C1276947 @default.
• W4225530712 hasConceptScore W4225530712C187212893 @default.
• W4225530712 hasConceptScore W4225530712C203014093 @default.
• W4225530712 hasConceptScore W4225530712C203165030 @default.
• W4225530712 hasConceptScore W4225530712C22070199 @default.
• W4225530712 hasConceptScore W4225530712C2779134260 @default.
• W4225530712 hasConceptScore W4225530712C2780868878 @default.
• W4225530712 hasConceptScore W4225530712C3007834351 @default.
• W4225530712 hasConceptScore W4225530712C3008058167 @default.
• W4225530712 hasConceptScore W4225530712C524204448 @default.
• W4225530712 hasConceptScore W4225530712C71924100 @default.
• W4225530712 hasConceptScore W4225530712C72563966 @default.
• W4225530712 hasConceptScore W4225530712C8891405 @default.
• W4225530712 hasIssue "4" @default.
• W4225530712 hasLocation W42255307121 @default.
• W4225530712 hasLocation W42255307122 @default.
• W4225530712 hasLocation W42255307123 @default.
• W4225530712 hasOpenAccess W4225530712 @default.
• W4225530712 hasPrimaryLocation W42255307121 @default.
• W4225530712 hasRelatedWork W2162913520 @default.
• W4225530712 hasRelatedWork W2603773853 @default.
• W4225530712 hasRelatedWork W4200432472 @default.
• W4225530712 hasRelatedWork W4205317059 @default.
• W4225530712 hasRelatedWork W4205405760 @default.
• W4225530712 hasRelatedWork W4206669628 @default.
• W4225530712 hasRelatedWork W4308988359 @default.
• W4225530712 hasRelatedWork W4313274444 @default.
• W4225530712 hasRelatedWork W4313384190 @default.
• W4225530712 hasRelatedWork W4379259746 @default.
• W4225530712 hasVolume "22" @default.
• W4225530712 isParatext "false" @default.
• W4225530712 isRetracted "false" @default.
• W4225530712 workType "article" @default.